Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects

Phase 1 Completed 32 enrolled Novartis

RandomizedCrossoverTriple-blindTreatment

This study is designed to investigate the safety and tolerability of PTH134 in healthy subjects and to assess the exposure from PTH134.

Evaluation	Drug	Modality	Dose	Route
Subject	Teriparatide	Protein / enzyme biologic	1 mg	Oral
Subject	Teriparatide	Protein / enzyme biologic	2.5 mg	Oral
Subject	Teriparatide	Protein / enzyme biologic	5 mg	Oral
Subject	Teriparatide	Protein / enzyme biologic	10 mg	Oral